Multiple primary melanoma

Dermatologic Surgery

Volumn 25, Issue 7, 1999, Pages 576-581

  Conrad, Nicole ^a   Leis, Paula ^a   Orengo, Ida ^a,b   Medrano, Estela E ^b   Hayes, Teresa G ^b   Baer, Susan ^a   Rosen, Theodore ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER RISK; CANCER SURGERY; CASE REPORT; FAMILIAL CANCER; FAMILY HISTORY; GENETIC SUSCEPTIBILITY; HUMAN; MALE; MELANOMA; PRIORITY JOURNAL; SKIN BIOPSY; SKIN METASTASIS;

BIOPSY; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS, MULTIPLE PRIMARY; SKIN; SKIN NEOPLASMS;

EID: 0032801999     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4725.1999.98050.x     Document Type: Article

References (70)

1. Ries LAG, Hankey BF, Miller BA, et al. Cancer Statistics Review 1973-1988. Surveillance Epidemiology and End Results (SEER) Database. NIH publication no. 91-2789. Bethesda, MD: National Cancer Institute, 1991.
2. Johnson TM, Smith JW, Nelson BR, et al. Current therapy for cutaneous melanoma. J Am Acad Dermatol 1995;32:689-707.
3. Weinstock MA. Statistics of interest to the dermatologist. In: Sober AJ, Fitzpatrick TB, eds. Yearbook of Dermatology. St. Louis: Mosby-Year Book, 1993:48.
4. Evans RD, Kopf AW, Lew RA, et al. Risk factors for the development of malignant melanoma I: review of case controlled studies. J Dermatol Surg Oncol 1988;14:393-408.
5. Greene MH, Fraumeni JF. The hereditary variant of malignant melanoma. In: Clark WH, Goldman L, Mastrangelo M, eds. Human Malignant Melanoma. New York: Grune and Stratton, 1979:139-66.
6. Barnhill RL, Mihm MC Jr, Fitzpatrick TB, et al. Neoplasms: malignant melanoma. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al., eds. Dermatology in General Medicine, 4th ed. New York: McGraw-HiIl, 1993:1078-115.
7. Rigel DS, Rivers JK, Friedman RJ, et al. Risk gradient for malignant melanoma in individuals with dysplastic naevi. Lancet 1988;1: 352-3.
8. Tiersten AD, Grin CM, Kopf AW, et al. Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-nevus) syndrome. J Dermatol Surg Oncol 1991;17:44-8.
9. Halpern AC, Guerry D IV, Elder DE, et al. A cohort study of melanoma in patients with dysplastic nevi. J Invest Dermatol 1993;100: S350-5.
10. Kang S, Barnhill RL, Mihm MC, et al. Multiple primary cutaneous melanomas. Cancer 1992;70:1911-6.
11. Rigel DS, Rivers JK, Kopf AW, et al. Dysplastic nevi: markers for increased risk for melanoma. Cancer 1989;63:386-9.
12. Parmiter AH, Noweli PC. Cytogenetics of melanocytic tumors. J Invest Dermatol 1993;100(suppl):S254-8.
13. Swerdlow AJ, English J, MacKie RM, et al. Benign nevi as a risk factor for malignant melanoma. Br Med J 1986;292:1555-9.
14. Weiss J, Schwechheimner K, Cavenee WK, et al. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int J Cancer 1993;54:693-9.
15. Akslen LA, Morkve O. Expression of p53 protein in cutaneous melanoma. Int J Cancer 1992;52:13-6.
16. Lynch HT, Fusaro RM, Pester J, et al. Tumor spectrum in the FAMMM syndrome. Br J Cancer 1981;44:553-60.
17. Slade J, Ashfaq AM, Salopek TG, et al. Atypical mole syndrome: risk factor for cutaneous malignant melanoma and implications for management. J Am Acad Dermatol 1995;32:479-94.
18. Nordlund JJ, Kirkwood J, Forget BM, Scheibner A, et al. Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res 1985;45:1855-61.
19. Halpern AC, Guerry D IV, Elder DE, et al. Dyslpastic nevi as risk markers of sporadic (nonfamilial) melanoma: a case-control study. Arch Dermatol 1991;127:995-9.
20. Augustsson A, Stierner U, Rosdahl I, et al. Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. Acta Derm Venereol (Stockh) 1991;71:518-24.
21. Holly EA, Kelly JW, Shpall SN, et al. Number of melanocytic nevi as a risk factor for malignant melanoma. J Am Acad Dermatol 1987;17:459-68.
22. Garbe C, Kruger S, Stadler R, et al. Markers and relative risk in a German population for developing malignant melanoma. Int J Dermatol 1989;28:517-23.
23. Rhodes AR. If detected early, malignant melanoma can be treated successfully. Dermatol Times 1997;Aug(suppl):S5-S9.
24. Greene M, Clark WH Jr, Tucker MA, et al. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985;102:458-65.
25. Tucker MA, Fraser MC, Goldstein AM, et al. Risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol 1993;100:350S-5S.
26. Carey WP Jr, Thompson CJ, Synnestvedt M, et al. Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer 1994;74:3118-25.
27. Pack GT, Scharnagel JM, Hiegler RA. Multiple primary melanoma. Cancer 1952;5:1110-5.
28. Beardmor GL, Davis NC. Multiple primary cutaneous melanomas. Arch Dermatol 1975;111:603-9.
29. Anderson DE, Smith JL, McBride CM. Hereditary aspects of malignant melanoma. JAMA 1967;200:741-6.
30. Lynch HT, Frichot BC, Lynch P, et al. Family studies of malignant melanoma and associated cancer. Surg Gynecol Obstet 1975;141: 517-22.
31. Bellet RE, Vaisman I, Mastrangelo MJ, et al. Multiple primary melanoma. Cancer 1977;40:1974-81.
32. Cascinelli N, Fontana V, Cataldo I, et al. Multiple primary melanoma. Tumori 1975;61:481-6.
33. Clark WH, Reiner RC, Greene M, et al. Origin of familial malignant melanomas from heritable melanocytic lesions. Arch Dermatol 1978;114:732-8.
34. Moseley HS, Giuliano AE, Storm FK, et al. Multiple primary melanoma. Cancer 1979;43:939-44.
35. Wallace DC, Beardmore GL, Exton LA, et al. Familial malignant melanoma. Ann Surg 1973;177:15-20.
36. Anderson DE. Clinical characteristics of the genetic variety of cutaneous melanoma in man. Cancer 1971;28:721-5.
37. Bork K, Brauninger W, Nake A. Increased frequency of multiple primary melanomas in hereditary familial melanoma. Dermatologica 1981;162:191-6.
38. Tucker M, Bale SJ. Clinical aspects of familial cutaneous malignant melanoma. Semin Oncol 1988;15:524-8.
39. Bale SJ, Dracopoli NC, Tucker MA, et al. Mapping the gene for hereditary cutaneous melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 1989;320:1367-72.
40. Sigg C, Pellone F, Schnyder UW. Gehaufte mehrfachmelanome bei sporadischen und familiaren dysplastischen navuszellnavus-syndrome. Hartarzt 1989;40:548-52.
41. Veronesi U, Cascinelle N, Bufalino R. Evaluation of the risk of multiple primaries in malignant cutaneous melanoma. Tumori 1976;62:127.
42. Ariyan S, Poo WJ, Bolognia J, et al. Multiple primary melanomas: data and significance. Plast Reconstr Surg 1995;96:1384.
43. Masri GD, Clark WH Jr, Guerry D IV, et al. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol 1990;22: 1042-8.
44. Petty EM, Gibson LH, Fountain JW, et al. Molecular definition of a chromosome 9p21 germ-line deletion in a woman with multiple melanomas and a plexiform neurofibroma: implications for 9p tumor-suppressor gene(s). Am J Hum Genet 1993;53:96-104.
45. Trent JM, Stanbridge EJ, McBride HL, et al. Tumorigenicity in human melanoma cell lines controlled by introduction human chromosome 6. Science 1990;247:568-71.
46. Piepkorn MW. Genetic basis of susceptibility to melanoma. J Am Acad Dermatol 1994;31:1022-39.
47. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992;258:1148-51.
48. Meyer L, Zone J. Genetics of cutaneous melanoma. J Invest Dermatol 1994;103:S112-S116.
49. Greene MH, Goldin LR, Clark WHJ, et al. Familial cutaneous malignant melanoma: autosomal dominant trait possible linked to the Rh locus. Proc Natl Acad Sci USA 1983;80:6071-5.
50. van Haeringen A, Bergman W, Nelen MR, et al. Exclusion of the dysplastic nevus syndrome (DNS) locus from the short arm of chromosome 1 by linkage studies in Dutch families. Genomies 1989;5: 61-4.
51. Cannon-Albright L, Goldgar D, Wright E, et al. Evidence against the reported linkage of the cutaneous melanoma-dysplastic nevus syndrome locus to chromosome 1. Am J Hum Genet 1990;46: 912-8.
52. Kefford RF, Salmon J, Shaw HM, et al. Hereditary melanoma in Australia. Variable association with dysplastic nevi and absence of genetic linkage to chromosome 1p. Cancer Genet Cytogenet 1991; 51:45-55.
53. Gruis NA, Bergman W, Frants RR. Locus for susceptibility to melanoma on chromosome 1p. N Engl J Med 1990;322:853-4.
54. Nancarrow DJ, Palmer JM, Walters MK, et al. Exclusion of the familial melanoma locur (MLM) from the PND/D1S47 and MYCL 1 regions of chromosome arm 1p in 7 Australian pedigrees. Genomies 1992;12:18-25.
55. Reed JA, Loganzo F, Shea C, et al. Loss of expression of the p16/ cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995;55:2713-8.
56. Lynch HT, Frichot BC, Lynch JF. Familial atypical mole syndrome. J Med Genet 1978;15:352-6.
57. Greene MH, Remier RR, Clark WHJ, et al. Precursor lesions in familial melanoma. Semin Oncol 1978;5:85-97.
58. Fountain JW, Karayiorgou M, Ernstoff MS, et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Am J Hum Genet 1993;53:96-104.
59. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/Cdk4. Nature 1993;366:704-7.
60. Weinberg RA. The molecular basis of carcinogenesis: understanding the cell cycle clock. Cytokine Mol Ther 1996;2:105-10.
61. INK4a expression and its implication for cell immortalization and senescence. Mol Cell Biol 1996;16:859-67.
62. Haddad M, Xu M, Medrano EE. Aging in epidermal melanocytes: cell cycle genes and melanins. J Invest Dermatol Symp Proc 1998;3: 36-40.
63. INK4a expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol 1995;15:4745-53.
64. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264:436-40.
65. Nobori T, Miura K, Wu DJ, et al. Kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-6.
66. Costello JF, Berger MS, Su Huang H-J, Cavenee WK. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 1996;56:2405-10.
67. Clurman BE, Roberts JM. Cell Cycle & Cancer. J Natl Cancer Inst 1995;87:1499-1501.
68. Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK mutations. N Engl J Med 1995;333:970-4.
69. Kinzler KW, Nilbert MG, Su LK, et al. Identification of FAP locus genes from chromosome 5q21. Science 1991;253:661-5.
70. National Institutes of Health Consensus Development Panel on Early Melanoma. Diagnosis and treatment of early melanoma. JAMA 1992;268:1314-9.